https://www.selleckchem.com/pr....oducts/Celastrol.htm
lotinib could be promising candidates for the site-specific treatment of colon cancer with the least detrimental side-effects. These studies indicate that polyphosphazene linked drug conjugates of erlotinib could be promising candidates for the site-specific treatment of colon cancer with the least detrimental side-effects. The growing prevalence of cancer and the resulting chemoresistance exert not only a great healthcare burden but is also a great challenge to public health, worldwide. In search of new chemical entities against canc
Like
Comment
Share
